Related Experiment Video
Updated: May 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study
Julio A Lamprea-Montealegre1, A Richey Sharrett2, Kunihiro Matsushita2
1Department of Medicine, University of Maryland School of Medicine, United States.
Insights
Chronic kidney disease (CKD) increases coronary heart disease (CHD) risk. While apolipoprotein B to A-1 ratio (ApoB/A1) is higher in CKD, it showed no stronger association with CHD risk than other lipid ratios.
Area of Science:
- Cardiology
- Nephrology
- Lipidology
Background:
- Chronic kidney disease (CKD) is linked to higher apolipoprotein B to A-1 ratio (ApoB/A1).
- The comparative association of ApoB/A1 with coronary heart disease (CHD) risk in CKD versus traditional lipid ratios is unclear.
Purpose of the Study:
- To investigate the association of ApoB/A1 and non-HDL-cholesterol to HDL-cholesterol ratio (NonHDLc/HDLc) with incident CHD in individuals with and without CKD.
- To compare the strength of association of these markers with CHD risk between CKD and non-CKD populations.
Main Methods:
- Analysis of 10,137 individuals from the ARIC study, defining CKD by estimated glomerular filtration rate (<60 ml/min/1.73 m²).
- Utilized Cox proportional hazards regression to assess the association of lipid and apolipoprotein markers with incident CHD.
- Adjusted for demographic and clinical cardiovascular risk factors.
Main Results:
- CKD was present in 12% of participants and associated with a higher incidence of CHD events (12.0 vs. 5.2 per 1000 person-years).
- Individuals with CKD had lower ApoA1 and higher ApoB/A1 compared to those without CKD.
- Both ApoB/A1 and NonHDLc/HDLc were associated with increased CHD risk in CKD, with no significant difference in strength compared to non-CKD participants.
Conclusions:
- CKD is associated with dyslipidemia, including lower ApoA1 and higher ApoB/A1.
- ApoB/A1 is not more strongly associated with CHD incidence in CKD patients than NonHDLc/HDLc.
Background:
Chronic kidney disease (CKD) is associated with elevated apolipoprotein B to A-1 ratio (ApoB/A1). It is not known whether these markers are more strongly associated with the risk of coronary heart disease (CHD) in CKD compared to traditionally measured lipids and lipoprotein cholesterol ratios.
Methods:
We studied the association of lipids and apolipoproteins including non-HDL-cholesterol to HDL-cholesterol ratio (NonHDLc/HDLc) and ApoB/A1 with incident CHD in 10,137 individuals free of CHD at baseline (visit four) in the Atherosclerosis Risk in Communities (ARIC) study. An estimated glomerular filtration rate of 15 to <60 ml/min/1.73 m(2) based on a cystatin C measurement was used to define CKD (Stage 3-4). Cox proportional hazards regression models were used to determine the association of lipids and apolipoprotein measurements with the risk of CHD in those with and without CKD after adjustment for demographic and known clinical cardiovascular risk factors.
Results:
CKD was present in 1217 (12%) individuals free of CHD at baseline. The median follow-up time was 11.1 years. A CHD event developed in 498 out of 8920 individuals without CKD (incidence rate: 5.2 events per 1000 person-years) and in 138 out of 1217 individuals with CKD (incidence rate: 12.0 events per 1000 person-years; P < 0.001). Those with CKD had a lower concentration of ApoA1: median (in g/L) and interquartile range (IQR) = 1.40 (1.38-1.42) vs. 1.48 (1.47-1.49) P < 0.001; and a higher ApoB/A1 = 0.75 (0.73-0.77) vs. 0.71 (0.70-0.72) P < 0.001; than those without CKD (eGFR ≥ 60 ml/min/1.73 m(2)). Among individuals with CKD, ApoB/A1 and NonHDLc/HDLc were both associated with the risk of CHD: hazard ratios (HR) and 95% confidence intervals (CI) per one standard deviation increase = 1.22 (1.02-1.46) for ApoB/A1 and 1.30 (1.07-1.57) for NonHDLc/HDLc with no significant differences detected (P for interaction >0.1) when comparing these estimates to those of participants without CKD.
Conclusions:
Although CKD is associated with a lower ApoA1 concentration and with a higher ApoB/A1, we found no evidence that these apolipoproteins are more strongly associated with CHD incidence in CKD compared to NonHDLc/HDLc.
Related Concept Videos
Coronary Artery Disease I: Introduction
Atherosclerosis I: Introduction
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease II: Pathophysiology

